Cargando…
Liraglutide Improves the Angiogenic Capability of EPC and Promotes Ischemic Angiogenesis in Mice under Diabetic Conditions through an Nrf2-Dependent Mechanism
The impairment in endothelial progenitor cell (EPC) functions results in dysregulation of vascular homeostasis and dysfunction of the endothelium under diabetic conditions. Improving EPC function has been considered as a promising strategy for ameliorating diabetic vascular complications. Liraglutid...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9736458/ https://www.ncbi.nlm.nih.gov/pubmed/36497087 http://dx.doi.org/10.3390/cells11233821 |
_version_ | 1784847033294651392 |
---|---|
author | Yan, Xiaoqing Su, Yue Fan, Xia Chen, Hui Lu, Zixian Liu, Zijuan Li, Yingjian Yi, Mei Zhang, Guigui Gu, Chunjie Wang, Kai Wu, Jiamin Sun, Da Zhang, Yikai Zhang, Chi Dai, Xiaozhen Zheng, Chao |
author_facet | Yan, Xiaoqing Su, Yue Fan, Xia Chen, Hui Lu, Zixian Liu, Zijuan Li, Yingjian Yi, Mei Zhang, Guigui Gu, Chunjie Wang, Kai Wu, Jiamin Sun, Da Zhang, Yikai Zhang, Chi Dai, Xiaozhen Zheng, Chao |
author_sort | Yan, Xiaoqing |
collection | PubMed |
description | The impairment in endothelial progenitor cell (EPC) functions results in dysregulation of vascular homeostasis and dysfunction of the endothelium under diabetic conditions. Improving EPC function has been considered as a promising strategy for ameliorating diabetic vascular complications. Liraglutide has been widely used as a therapeutic agent for diabetes. However, the effects and mechanisms of liraglutide on EPC dysfunction remain unclear. The capability of liraglutide in promoting blood perfusion and angiogenesis under diabetic conditions was evaluated in the hind limb ischemia model of diabetic mice. The effect of liraglutide on the angiogenic function of EPC was evaluated by cell scratch recovery assay, tube formation assay, and nitric oxide production. RNA sequencing was performed to assess the underlying mechanisms. Liraglutide enhanced blood perfusion and angiogenesis in the ischemic hindlimb of db/db mice and streptozotocin-induced type 1 diabetic mice. Additionally, liraglutide improved tube formation, cell migration, and nitric oxide production of high glucose (HG)-treated EPC. Assessment of liraglutide target pathways revealed a network of genes involved in antioxidant activity. Further mechanism study showed that liraglutide decreased the production of reactive oxygen species and increased the activity of nuclear factor erythroid 2-related factor 2 (Nrf2). Nrf2 deficiency attenuated the beneficial effects of liraglutide on improving EPC function and promoting ischemic angiogenesis under diabetic conditions. Moreover, liraglutide activates Nrf2 through an AKT/GSK3β/Fyn pathway, and inhibiting this pathway abolished liraglutide-induced Nrf2 activation and EPC function improvement. Overall, these results suggest that Liraglutide represents therapeutic potential in promoting EPC function and ameliorating ischemic angiogenesis under diabetic conditions, and these beneficial effects relied on Nrf2 activation. |
format | Online Article Text |
id | pubmed-9736458 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-97364582022-12-11 Liraglutide Improves the Angiogenic Capability of EPC and Promotes Ischemic Angiogenesis in Mice under Diabetic Conditions through an Nrf2-Dependent Mechanism Yan, Xiaoqing Su, Yue Fan, Xia Chen, Hui Lu, Zixian Liu, Zijuan Li, Yingjian Yi, Mei Zhang, Guigui Gu, Chunjie Wang, Kai Wu, Jiamin Sun, Da Zhang, Yikai Zhang, Chi Dai, Xiaozhen Zheng, Chao Cells Article The impairment in endothelial progenitor cell (EPC) functions results in dysregulation of vascular homeostasis and dysfunction of the endothelium under diabetic conditions. Improving EPC function has been considered as a promising strategy for ameliorating diabetic vascular complications. Liraglutide has been widely used as a therapeutic agent for diabetes. However, the effects and mechanisms of liraglutide on EPC dysfunction remain unclear. The capability of liraglutide in promoting blood perfusion and angiogenesis under diabetic conditions was evaluated in the hind limb ischemia model of diabetic mice. The effect of liraglutide on the angiogenic function of EPC was evaluated by cell scratch recovery assay, tube formation assay, and nitric oxide production. RNA sequencing was performed to assess the underlying mechanisms. Liraglutide enhanced blood perfusion and angiogenesis in the ischemic hindlimb of db/db mice and streptozotocin-induced type 1 diabetic mice. Additionally, liraglutide improved tube formation, cell migration, and nitric oxide production of high glucose (HG)-treated EPC. Assessment of liraglutide target pathways revealed a network of genes involved in antioxidant activity. Further mechanism study showed that liraglutide decreased the production of reactive oxygen species and increased the activity of nuclear factor erythroid 2-related factor 2 (Nrf2). Nrf2 deficiency attenuated the beneficial effects of liraglutide on improving EPC function and promoting ischemic angiogenesis under diabetic conditions. Moreover, liraglutide activates Nrf2 through an AKT/GSK3β/Fyn pathway, and inhibiting this pathway abolished liraglutide-induced Nrf2 activation and EPC function improvement. Overall, these results suggest that Liraglutide represents therapeutic potential in promoting EPC function and ameliorating ischemic angiogenesis under diabetic conditions, and these beneficial effects relied on Nrf2 activation. MDPI 2022-11-29 /pmc/articles/PMC9736458/ /pubmed/36497087 http://dx.doi.org/10.3390/cells11233821 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Yan, Xiaoqing Su, Yue Fan, Xia Chen, Hui Lu, Zixian Liu, Zijuan Li, Yingjian Yi, Mei Zhang, Guigui Gu, Chunjie Wang, Kai Wu, Jiamin Sun, Da Zhang, Yikai Zhang, Chi Dai, Xiaozhen Zheng, Chao Liraglutide Improves the Angiogenic Capability of EPC and Promotes Ischemic Angiogenesis in Mice under Diabetic Conditions through an Nrf2-Dependent Mechanism |
title | Liraglutide Improves the Angiogenic Capability of EPC and Promotes Ischemic Angiogenesis in Mice under Diabetic Conditions through an Nrf2-Dependent Mechanism |
title_full | Liraglutide Improves the Angiogenic Capability of EPC and Promotes Ischemic Angiogenesis in Mice under Diabetic Conditions through an Nrf2-Dependent Mechanism |
title_fullStr | Liraglutide Improves the Angiogenic Capability of EPC and Promotes Ischemic Angiogenesis in Mice under Diabetic Conditions through an Nrf2-Dependent Mechanism |
title_full_unstemmed | Liraglutide Improves the Angiogenic Capability of EPC and Promotes Ischemic Angiogenesis in Mice under Diabetic Conditions through an Nrf2-Dependent Mechanism |
title_short | Liraglutide Improves the Angiogenic Capability of EPC and Promotes Ischemic Angiogenesis in Mice under Diabetic Conditions through an Nrf2-Dependent Mechanism |
title_sort | liraglutide improves the angiogenic capability of epc and promotes ischemic angiogenesis in mice under diabetic conditions through an nrf2-dependent mechanism |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9736458/ https://www.ncbi.nlm.nih.gov/pubmed/36497087 http://dx.doi.org/10.3390/cells11233821 |
work_keys_str_mv | AT yanxiaoqing liraglutideimprovestheangiogeniccapabilityofepcandpromotesischemicangiogenesisinmiceunderdiabeticconditionsthroughannrf2dependentmechanism AT suyue liraglutideimprovestheangiogeniccapabilityofepcandpromotesischemicangiogenesisinmiceunderdiabeticconditionsthroughannrf2dependentmechanism AT fanxia liraglutideimprovestheangiogeniccapabilityofepcandpromotesischemicangiogenesisinmiceunderdiabeticconditionsthroughannrf2dependentmechanism AT chenhui liraglutideimprovestheangiogeniccapabilityofepcandpromotesischemicangiogenesisinmiceunderdiabeticconditionsthroughannrf2dependentmechanism AT luzixian liraglutideimprovestheangiogeniccapabilityofepcandpromotesischemicangiogenesisinmiceunderdiabeticconditionsthroughannrf2dependentmechanism AT liuzijuan liraglutideimprovestheangiogeniccapabilityofepcandpromotesischemicangiogenesisinmiceunderdiabeticconditionsthroughannrf2dependentmechanism AT liyingjian liraglutideimprovestheangiogeniccapabilityofepcandpromotesischemicangiogenesisinmiceunderdiabeticconditionsthroughannrf2dependentmechanism AT yimei liraglutideimprovestheangiogeniccapabilityofepcandpromotesischemicangiogenesisinmiceunderdiabeticconditionsthroughannrf2dependentmechanism AT zhangguigui liraglutideimprovestheangiogeniccapabilityofepcandpromotesischemicangiogenesisinmiceunderdiabeticconditionsthroughannrf2dependentmechanism AT guchunjie liraglutideimprovestheangiogeniccapabilityofepcandpromotesischemicangiogenesisinmiceunderdiabeticconditionsthroughannrf2dependentmechanism AT wangkai liraglutideimprovestheangiogeniccapabilityofepcandpromotesischemicangiogenesisinmiceunderdiabeticconditionsthroughannrf2dependentmechanism AT wujiamin liraglutideimprovestheangiogeniccapabilityofepcandpromotesischemicangiogenesisinmiceunderdiabeticconditionsthroughannrf2dependentmechanism AT sunda liraglutideimprovestheangiogeniccapabilityofepcandpromotesischemicangiogenesisinmiceunderdiabeticconditionsthroughannrf2dependentmechanism AT zhangyikai liraglutideimprovestheangiogeniccapabilityofepcandpromotesischemicangiogenesisinmiceunderdiabeticconditionsthroughannrf2dependentmechanism AT zhangchi liraglutideimprovestheangiogeniccapabilityofepcandpromotesischemicangiogenesisinmiceunderdiabeticconditionsthroughannrf2dependentmechanism AT daixiaozhen liraglutideimprovestheangiogeniccapabilityofepcandpromotesischemicangiogenesisinmiceunderdiabeticconditionsthroughannrf2dependentmechanism AT zhengchao liraglutideimprovestheangiogeniccapabilityofepcandpromotesischemicangiogenesisinmiceunderdiabeticconditionsthroughannrf2dependentmechanism |